STEVE ASELAGE
CIK 1221599 · Chief Executive Officer · last filed 2024-06-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$20.74M
Companies
7
Total Filings
114
Lifetime Open-Market Net
-$21.13M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BCRX | Director | 72,659 | $9.38 | $681.5K | $65.1K | 23 | 2024-06-14 |
| Acer Therapeutics Inc. (ACER) Delisted | Director | 483,741 | $0.66 | $319.3K | $696.7K | 9 | 2023-03-16 |
| TVTX | Director | 166,419 | $61.32 | $10.20M | -$4.97M | 12 | 2022-05-12 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Director | 233,732 | — | — | -$3.46M | 32 | 2020-11-06 |
| Acer Therapeutics Inc. (ACERW) Delisted | Director | 13,905 | — | — | $24.0K | 2 | 2017-12-18 |
| Acer Therapeutics Inc. (OPXAW) Delisted | Director | 11,905 | — | — | $0 | 1 | 2017-09-21 |
| BMRN | EVP, Chief Business Officer | 154,375 | $63.81 | $9.85M | -$13.49M | 33 | 2012-07-05 |
Recent Filings · Page 6 of 12
114 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-05-24 | BCRX | Buy (P) | +3,000 | $10.7K | EDGAR |
| 2019-05-16 | Travere Therapeutics, Inc. (RTRX) Delisted | Sell (S) | −3,676 | -$65.5K | EDGAR |
| 2019-05-10 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +2,000 | $0 | EDGAR |
| 2019-03-14 | BCRX | Buy (P) | +2,000 | $16.6K | EDGAR |
| 2019-02-13 | Travere Therapeutics, Inc. (RTRX) Delisted | Sell (S) | −2,130 | -$45.7K | EDGAR |
| 2019-02-05 | Acer Therapeutics Inc. (ACER) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-01-08 | BCRX | Grant (A) | — | $0 | EDGAR |
| 2018-12-21 | Travere Therapeutics, Inc. (RTRX) Delisted | Sell (S) | −12,376 | -$270.8K | EDGAR |
| 2018-12-20 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +20,625 | $0 | EDGAR |
| 2018-12-07 | Travere Therapeutics, Inc. (RTRX) Delisted | Mixed | −1,760 | -$240 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.